DT120 ODT shows positive Phase 3 results in generalized anxiety disorder
Definium Therapeutics announced positive top-line results from its Phase 3 Panorama study of DT120 ODT in GAD, marking the third positive Phase 3 data readout for the drug and anticipated progress towards regulatory filing.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day